NCT02667873View on ClinicalTrials.gov

A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

October 6, 2021

Study Completion Date

October 13, 2021

Conditions
Solid Tumors
Interventions
DRUG

SL-801

SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).

Trial Locations (6)

34236

Florida Cancer Specialist, Sarasota

37203

Sarah Cannon Research Institute, Nashville

75230

Mary Crowely Cancer Research Centers- Medical City, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

98109

University of Washington, Seattle Cancer Care Alliance, Seattle

06520

Yale Cancer Center, New Haven

All Listed Sponsors
lead

Stemline Therapeutics, Inc.

INDUSTRY

NCT02667873 - A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter